Aliskiren: A clinical profile

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue SUPPL. 2, 2006, Pages

  Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Aliskiren; Antihypertensive agents; Hypertension; Renin inhibitor

Indexed keywords

ALISKIREN; AMLODIPINE; ATENOLOL; CELECOXIB; CIMETIDINE; DIGOXIN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; MEVINOLIN; PLACEBO; RAMIPRIL; RENIN; WARFARIN;

ADD ON THERAPY; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EDEMA; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LONG TERM CARE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; PATIENT COMPLIANCE; PLASMA RENIN ACTIVITY; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

EID: 33847698544     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.033     Document Type: Article

References (19)

1. Primatesta P, Poulter NR. Improvement in hypertension management in England: results from the Health Survey for England 2003.J Hypertens 2006;24:1187-92.
2. NICE Clinical Guideline 34. National Institute for Health and Clinical Excellence, June 2006. ISBN 1-84629-222-0. www.nice.org.uk
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
4. Burke TA, Sturkenboom MC, Lu SE et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006;24:1193-200.
5. Vaidyanathan S, Limoges D, Yeh C, Dieterich H. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2006;79:64(PIII-23).
6. Vaidyanathan S, Zhao C, Yeh C, Dieterich H. Pharmacokinetics and safety of the novel oral renin inhibitor aliskiren in patients with type 2 diabetes. Clin Pharmacol Ther 2006;79:64(PI-21).
7. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24:243-56.
8. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004;58:433-6.
9. Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005;43:527-35.
10. Dieterich H, Kemp C, Vaidyanathan S, Yeh C. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 2006;79:64(PIII-24).
11. Dieterich H, Kemp C, Vaidyanathan S, Yeh C. Pharmacokinetic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers. Clin Pharmacol Ther 2006;79:12(PI-20).
12. Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-18.
13. Weir MR, Bush C, Zhang J et al. Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Oral presentation at WCC/ESC congress, Barcelona, Spain, 2-6 September, 2006 (Abstract 1796).
14. Mitchell J, Oh B, Herron J et al. Once-daily aliskiren provides effective, smooth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens 2006;8(5 suppl. A):A93(P-209). Poster presented at ASH 2006.
15. Villamil A, Chrysant S, Calhoun D et al. The novel oral renin inhibitor aliskiren provides effective blood pressure control in patients with hypertension when used alone or in combination with hydrochlorothiazide. J Clin Hypertens 2006;8(5 suppl A):P-228.
16. Calhoun D, Chrysant S, Villamil A et al. The novel oral renin inhibitor aliskiren decreases plasma renin activity (PRA) and neutralizes hydrochlorothiazide-induced RAAS activation in hypertensive patients. J Clin Hypertens 2006;8(5):suppl A:P-168.
17. Uresin Y, Taylor A, Kilo C et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens 2006:24(suppl 4):S82 (P4.269).
18. Munger MA, Drummond W, Essop MR et al. Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Abstract presented at WCC/ESC, Barcelona, Spain, 2-6 September, 2006 (P784).
19. Sica D, Gradman A, Lederballe O et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Abstract presented at WCC/ESC, Barcelona, Spain, 2-6 September, 2006 (P797).